Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Owens & Minor $1 billion secured notes offering
The high-yield notes are due 2030
Insulet $419 million repurchases of convertible senior notes
We advised the agent on the transaction
Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Insulet $450 million senior notes offering
The high-yield notes are due 2033
Integer Holdings $1 billion convertible senior notes offering
The 1.875% convertible senior notes are due 2030
Nova Biomedical $2.2 billion acquisition by Advanced Instruments
We are advising Nova Biomedical on the transaction
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
Beam Therapeutics $500 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Endo divestiture of International Pharmaceuticals business
We are advising Endo on the transaction
Sycamore Partners up to $23.7 billion acquisition of Walgreens Boots Alliance
We are advising Sycamore Partners on the transaction